---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009978"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:32:36.991629+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# RenovoRx promotes Leesa Gentry to CCO; salary $325k, option for 190k shares

## Summary
- Leesa Gentry promoted from SVP of Clinical Operations to Chief Clinical Officer, effective March 1, 2024.
- Annual base salary of $325,000, with potential increase to $396,000 if CEO salary restored after 2024 reduction.
- Eligible for annual discretionary bonus up to 35% of base salary; for 2024 bonus not pro-rated.
- Received option to purchase 190,000 shares at $1.69 per share, vesting over 4 years in monthly installments.

## SEC filing metadata
- accession: 0001493152-24-009978
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/0001493152-24-009978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009978
- JSON: https://secwatch.observer/filing/0001493152-24-009978.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009978.txt

## Key facts
- Executive change
  Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..
  - Action: appointed
  - Role: Chief Clinical Officer
  source text: On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/0001493152-24-009978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.